At week @ in the per-protocol population , @ ( @ % ) of @ patients had virological response in the dual-treatment group versus @ ( @ % ) of @ in the triple-treatment group ( difference @ % -LSB- @ % CI -@ to @ % ) , showing non-inferiority at the prespecified level .